Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Completed

• Conditions: Hypertension
• Interventions: Drug: Olmesartan medoxomil

• Registration Number: NCT00796159
• Lead Sponsor: Pfizer

Brief Summary

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

Detailed Description

Non Probability Sampling

Study Timeline

• Study Start: 2007-07
• Study First Submitted: 2008-11-20
• Study First Submitted QC: 2008-11-21
• Study First Posted: 2008-11-24
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Status Verified: 2009-12
• Last Update Submitted: 2009-12-21
• Last Update Posted: 2009-12-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1723

Inclusion Criteria

• Male and Female patients 18 to 65 y/old
• Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP
• Patient with uncontrolled mild to moderate hypertension (SBP>= 140 and <=179 mmHg OR DBP of >=90 and <=109 mmHg)

Exclusion Criteria

• Pregnant of Lactating women
• History of secondary hypertension

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Olmesartan medoxomil + HCTZ	Olmesartan medoxomil	-

Primary Outcome Measures

Name	Time	Method
Safety (Adverse Events)	4 weeks

Secondary Outcome Measures

Name	Time	Method
Blood Pressure	4 weeks